| abstract |
A method of treating or reducing the risk of developing estrogen-related diseases including endometriosis (eg, estrogen-compromised), which is selective for patients with inhibition of ovarian secretion, for example by administering LHRH agonists or antagonists Administering an estrogen receptor modulator (SERM). In some embodiments, dihydroepiandrosterone (DHEA), dihydroepiandrosterone sulfate (DHEA-S), 4-androsten3,17-dione (5-dione) and androstenedione or one of these Sex steroid precursors selected from the group consisting of compounds are also administered. |